Name: GLP-1 Receptor Agonist Market Size & Trends 2035
Creator: Roots Analysis
Published: 2026-06-16T00:00:01+05:30
License: https://www.rootsanalysis.com/privacy.html
Keywords: GLP-1 Receptor Agonist Market, GLP-1 Receptor Agonist Market Growth, GLP-1 Receptor Agonist Market Trends, GLP-1 Receptor Agonist Market Size, GLP-1 Receptor Agonist Market Share, GLP-1 Receptor Agonist Market Analysis, GLP-1 Receptor Agonist Market Forecast, GLP-1 Receptor Agonist Market Report, Global GLP-1 Receptor Agonist Market, GLP-1 Receptor Agonist Industry

Market Outlook

The GLP-1 receptor agonist market size, valued at USD 78 billion in 2025, is projected to reach USD 101.4 billion in 2026 and USD 180 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035.

Global GLP-1 Receptor Agonist Market Growth, 2025 to 2035

See What’s in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of type of molecule, small molecules hold the highest GLP-1 receptor agonist market share (nearly 55%).
With respect to active compound used, semaglutide dominates the current market.
Based on the type of GLP-1 agonist drugs, long-acting GLP-1 agonists capture the largest share of the market, and the trend is unlikely to change in the future.
In terms of GLP-1 agonist, single-agonist therapies hold the highest share (nearly 80%) of the market.
With respect to route of administration, the parenteral route dominates the current market.
Based on the target indication, type 2 diabetes segment captures the largest share of the market, and the trend is unlikely to change in the future.
In terms of geographical regions, North America currently accounts for the largest market share, while Asia-Pacific is expected to grow at the highest pace in the coming years.

Key Market Statistics

Market Size in 2026: $101.4 Billion
Estimated Market Size in 2035: $180 Billion
CAGR (2026-2035): 6.6%
North America: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Introduction

GLP-1 receptor agonists are a class of medications primarily utilized for managing blood sugar levels in individuals with type 2 diabetes. Studies have shown that a few GLP-1 agonist drugs can also help in the treatment of obesity and related heart disease (cardiovascular disease). It is important to mention that, according to a study conducted by The Lancet, 42.4% of adult individuals in the US are obese.

In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which is likely to spur innovation and market expansion in this domain.

In order to meet the increasing demand for type 2 diabetes and body weight management therapies, various players are developing drugs for the treatment of these indications; of these, GLP-1 receptor agonists have emerged as a promising option driven by the significant number of positive clinical trial results. Continuous research and development efforts are now focused on next-generation GLP-1 peptides, including oral small-molecule formulations and dual agonists.

Over the past few years, a number of top GLP-1 drugs (as obesity and type 2 diabetes treatments) have received regulatory approvals globally. Recently, the FDA has approved Rybelsus® (developed by Novo Nordisk) for adults with type 2 diabetes and high cardiovascular risk in order to reduce the threat of major adverse cardiovascular events (MACE), such as heart attack and stroke. In addition, the FDA has also approved first GLP-1 generic to Teva’s Saxenda® (liraglutide injection) for weight loss. Given the lucrative potential of these drugs, the GLP-1 receptor agonist market, has gained significant attention from both private and public investors leading to substantial market growth during the forecast period.

Your Business is Unique – Why Shouldn’t Your Report Be?

Key Players & Their Flagship GLP-1 Receptor Agonist Drug Products

The current market landscape is highly competitive and dynamic. The table presented highlights the key companies and their flagship GLP-1 receptor agonist drug products.

Company	Year of Establishment	Headquarters	Drug Name	Type	Primary Indication
Eli Lilly	1876	US	Tirzepatide (Mounjaro, Zepbound)	Dual GLP-1/GIP agonist	Type 2 Diabetes and Obesity
Novo Nordisk	1923	Denmark	Semaglutide (Ozempic, Wegovy, Rybelsus)	GLP-1 agonist	Type 2 Diabetes and Obesity
AstraZeneca	1999	UK	Exenatide (Bydureon BCise)	GLP-1 agonist	Type 2 Diabetes
Sanofi	1973	France	Efpeglenatide	Long-acting GLP-1	Type 2 Diabetes

Market Segmentation

Based on the research, we have segmented the market into type of molecule, active compound used, type of GLP-1 agonist drugs, GLP-1 agonist, route of administration, target indication and geographical regions.

By Type of Molecule

Biologics
Small Molecules

By Active Compound Used

Dulaglutide
Liraglutide
Orforglipron
Retatrutide
Semaglutide
Survodutide
Tirzepatide
Other Active Compounds

By Type of GLP-1 Agonist Drug

Long-acting GLP-1 Agonist
Short-acting GLP-1 Agonist

By GLP-1 Agonist

Single-agonist
Dual-agonist
Tri-agonist

By Route of Administration

Oral
Parenteral

By Target Indication

Alzheimer’s Disease
Non-alcoholic Steatohepatitis
Obesity
Sleep Apnea
Type 2 Diabetes

By Geographical Regions

North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- New Zealand
- Rest of the Asia-Pacific
Latin America
- Argentina
- Brazil

GLP-1 Receptor Agonist Market Key Insights

What is the Market Opportunity for New Indications?

GLP-1 drugs target several indications, with type 2 diabetes being the first approved and primary indication for this drug class. Notably, in October 2025, the FDA approved Rybelsus (oral semaglutide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk. It is interesting to note that GLP-1 drugs are under evaluation for their antidepressant effects in preclinical studies. A group of researchers from various institutions in China evaluated dulaglutide, marketed under the brand name Trulicity.
Their rising uptake in patients seeking weight loss is also driving changes in food habits as the consumers seek healthier alternatives that meet nutritional needs. Major food companies such as Nestlé are seeking to capitalize on the opportunity created by changes in food preference for individuals taking GLP-1 peptides. In a recent interview with CNBC, Nestlé Former CEO Mark Schneider stated, “Nestlé will work on what we call companion products, products that really then address some of the specific consumer needs during weight loss treatment.” As such GLP-1 drugs are creating market opportunity not only for the biotech industry, but other industries as well.

What are the GLP-1 Receptor Agonist Market Restraints?

GLP1 drugs, like other pharmaceutical products, will lose patent protection over time, with Novo Nordisk’s Victoza positioned as the first GLP1 to face a U.S. patent expiry; the liraglutide (Victoza) patent expired in November 2024, and Teva Pharmaceuticals launched the first authorized generic in the US in June 2024, introducing a 1.8 mg dosage for glycemic control in adults with type 2 diabetes and for reducing major adverse cardiovascular events, while Sandoz also launched its generic in June 2024.
Semaglutide, the active ingredient in Ozempic Wegovy and Rybelsus, will lose U.S. patent exclusivity on 20 March 2026; in October 2024, Mylan settled a U.S. patent lawsuit with Novo Nordisk that grants Mylan and Indiabased Natco Pharma Sole firsttofile rights for certain U.S. generic semaglutide versions.
Although generics typically put pressure on the prices, GLP1 generics are expected to expand the overall market opportunity by improving affordability and availability across the drug class.

Recent Developments

In June 2026, AstraZeneca advanced its oral small-molecule GLP-1 receptor agonist elecoglipron into a comprehensive Phase III program following positive Phase IIb results showing significant weight loss and glycemic improvements.
In June 2026, the US Medicare program introduced an 18-month pilot initiative called “GLP-1 Bridge. The program will offer obesity medications such as Wegovy and Zepbound at approximately USD 50 per month.
In April 2026, Eli Lilly received FDA approval for orforglipron (Foundayo), its oral GLP-1 receptor agonist, for weight management in adults with obesity or overweight with comorbidities.
In March 2026, Structure Therapeutics reported positive Phase II results for its oral GLP-1 agonist aleniglipron, achieving substantial weight loss and advancing toward Phase III.
In December 2025, Novo Nordisk received FDA approval for its oral semaglutide Wegovy pill (25 mg), the first oral GLP-1 for weight management, with commercial rollout in early 2026.

Industry Experts on GLP-1 Receptor Agonist Market

The GLP-1 receptor agonist industry is experiencing profound growth and transformation, with industry leaders highlighting its disruptive impact on both healthcare and the global economy.

Professor Jura Liaukonyte (working as Associate Professor in the Charles H. Dyson School of Applied Economics and Management at Cornell University), stated that, “The pattern is less about switching to 'better' foods and more about simply buying less food. As GLP-1 adoption grows and new applications come to light, he mentioned that it could have sweeping impacts for both health outcomes and the economy. This shift could have notable implications for fast-moving consumer goods (FMCG) companies and food producers more broadly.”

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:

Chief Executive Officer, Large Organization, US
Associate Professor, Large Organization, US
Chief Scientific Officer, Large Organization, UK
Chief Commercial Officer, Mid-sized Organization, UK
Senior Account Executive, Large Organization, US
Chief Executive Officer, Large Organization, US
Chief Executive Officer, Large Organization, Denmark
Chief Scientific Adviser for Research, Large Organization, Denmark
Chief Executive Officer, Mid-sized Organization, India
Chief Medical Officer, Mid-sized Organization, US

Pay Only for What You Need – The Best Way to Optimize

Which Type of Molecule Captures the Largest GLP-1 Receptor Agonist Market Share?

Based on type of molecule, the global market is segmented into small molecules and biologics.

Currently, small molecules account for the largest share of the market, representing nearly 55% of the overall market. This dominance is primarily driven by the favorable drug development and manufacturing characteristics associated with small molecules. Compared with biologics, small molecules offer better formulation flexibility, lower production complexity, and cost-efficient large-scale manufacturing. In addition, their well-established development pathways and compatibility with conventional pharmaceutical production infrastructure have encouraged significant industry investment toward the development and commercialization of small molecule GLP-1 therapies.

Notably, biologics are expected to witness significant growth during the forecast period. This growth is driven by the favorable clinical performance of biologic GLP-1 therapies, which have demonstrated meaningful efficacy in glycemic control, weight management, and cardiovascular risk reduction. In addition, ongoing innovation in long-acting formulations and next-generation incretin therapies continue to support the expansion of biologic GLP-1 treatment options across multiple indications.

GLP-1 Receptor Agonist Market Share by Type of Molecule, 2026

Which Active Compound is Anticipated to Capture the Largest Share of the GLP-1 Receptor Agonist Market?

Based on active compound used, the market is segmented into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide, and other active compounds.

Currently, semaglutide accounts for the largest share of the market. This dominance is primarily driven by its broad commercial success across multiple indications including type 2 diabetes and obesity. Unlike many earlier GLP-1 therapies that were primarily positioned for diabetes management, semaglutide has significantly expanded the commercial potential of the drug class through its strong clinical outcomes in weight reduction. Further, the availability of semaglutide across multiple formulations has strengthened its market penetration and contributed to its dominance within the market.

Moreover, retatrutide and survodutide are expected to witness the highest growth during the forecast period. This growth is driven by increasing interest in next-generation incretin therapies capable of delivering enhanced efficacy across different metabolic disorders. Both candidates have demonstrated promising clinical outcomes and are being evaluated for their potential to address unmet needs beyond traditional glucose management.

Which type of GLP-1 Agonist Drug Holds the Largest Share in the GLP-1 Receptor Agonist Market?

Based on type of GLP-1 agonist drugs, the market is segmented into long-acting GLP-1 agonists and short-acting GLP-1 agonists.

Currently, long-acting GLP-1 agonists account for the largest share of the market. This is due to their ability to provide sustained receptor activation through less frequent dosing schedules, improving treatment adherence and supporting long-term disease management. Compared to short-acting therapies, long-acting GLP-1 agonists offer greater convenience for patients and healthcare providers, making them particularly suitable for chronic conditions that require continuous treatment.

It is worth highlighting that short-acting GLP-1 agonists are expected to witness notable growth during the forecast period. This growth is driven by ongoing efforts to expand treatment options for diverse patient populations and clinical scenarios. In certain settings, short-acting therapies may offer greater dosing flexibility and enable more individualized treatment approaches. As companies continue to explore new formulations and delivery technologies, short-acting GLP-1 agonists are expected to create significant opportunities for market growth.

Amongst Single-agonist, Dual-agonist, and Tri-agonist Therapies, Which Segment Holds the Largest Share in the GLP-1 Receptor Agonist Market?

Based on the GLP-1 agonist, the market is segmented into single-agonist, dual-agonist, and tri-agonist therapies.

Currently, single-agonist therapies account for the largest share (nearly 80%) of the market. This dominance is primarily driven by the presence of several commercially established single-agonist GLP-1 therapies that have been widely adopted across treatment settings. These therapies entered the market earlier than most dual- and tri-agonist candidates, enabling them to build substantial physician familiarity, generate extensive clinical evidence, and secure broad market access across major healthcare systems. As a result, single-agonist therapies continue to account for a significant proportion of overall GLP-1 receptor agonist market.

It is worth highlighting that tri-agonist therapies are expected to witness the highest growth during the forecast period. This growth is driven by increasing interest in next-generation therapies designed to simultaneously target multiple metabolic pathways. By engaging additional hormonal mechanisms beyond GLP-1 receptor activation, these therapies have demonstrated the potential to deliver enhanced weight reduction and broader metabolic benefits. As pharmaceutical companies continue to advance tri-agonist candidates through clinical development, the segment is expected to witness significant growth over the coming years.

Is Oral Route Catching up with the Parenteral Route?

Based on route of administration, the GLP-1 receptor agonist market is segmented into oral and parenteral routes.

Currently, the parenteral segment accounts for the largest share of the market, representing 93% of the overall revenue. This dominance can be attributed to the long-established clinical use of injectable GLP-1 therapies and the availability of several commercially available products across indications such diabetes and obesity.

Further, parenteral administration enables the delivery of peptide-based therapies directly into systemic circulation, improving drug absorption and helping maintain consistent therapeutic activity. The strong commercial performance of injectable products, coupled with continued innovation in long-acting formulations and combination therapies, is expected to further strengthen the leadership of this segment.

GLP-1 Receptor Agonist Market Size by Route of Administration, 2026 and 2035

On the other hand, the oral route is expected to witness the highest growth during the forecast period. This growth is driven by increasing patient preference for non-invasive treatment options and advancements in oral drug delivery technologies. Oral therapies have the potential to improve treatment adherence, reduce administration burden, and expand access among patients who may be reluctant to injectable therapies. As pharmaceutical companies continue to invest in next-generation oral GLP-1 receptor agonists, the segment is expected to witness substantial market expansion in the coming years.

Which Target Indication Accounts for the Largest Share of the GLP-1 Receptor Agonist Market?

Based on target indication, the market is segmented into Alzheimer's disease, non-alcoholic steatohepatitis, obesity, sleep apnea, and type 2 diabetes.

Currently, type 2 diabetes accounts for the largest share of the market. This dominance is primarily driven by the established use of GLP-1 receptor agonists in diabetes management and the extensive clinical evidence supporting their efficacy in glycemic control. GLP-1 therapies now represent an integral component of type 2 diabetes treatment regimens due to their ability to improve blood glucose regulation. In addition, they also provide benefits such as weight reduction and cardiovascular risk reduction. Further, the large patient population and widespread physician familiarity with these therapies have reinforced the segment's dominant position within the GLP-1 receptor agonist market.

It is worth highlighting that the non-alcoholic steatohepatitis (NASH) segment is expected to witness the highest growth during the forecast period. This growth is driven by the increasing interest in therapies capable of addressing both liver disease progression and the underlying metabolic dysfunction associated with NASH.

Since obesity, insulin resistance, and metabolic disorders play a significant role in disease development, GLP-1 receptor agonists have emerged as promising therapeutic candidates due to their effects on weight management and metabolic health. As clinical evidence supporting the use of GLP-1 therapies for NASH continues to expand, adoption within this indication is expected to increase significantly over the coming years.

Regional Analysis: Which Regions are Showing the Fastest Growth in GLP-1 Receptor Agonist Industry?

North America: Dominating the Market by Securing Highest Share

North America captures the majority of the market share (~75%). Several factors, such as the high prevalence of type 2 diabetes and obesity in the region, have resulted in a strong demand for effective treatments such as GLP-1 receptor agonists.

US GLP-1 Receptor Agonist Market

In the US, the high prevalence of type 2 diabetes and obesity, along with a well-established healthcare infrastructure, drives the adoption of GLP-1 agonist in the region. Physicians' widespread awareness (results in more healthcare providers being familiar with the benefits of GLP-1 receptor agonists) and favorable reimbursement policies (refer to insurance coverage and financial support that make these drugs accessible to patients) fuel the rapid adoption of GLP-1 agonist. Leading pharmaceutical companies are further accelerating market expansion by making significant investments to continuously expand manufacturing capabilities and introduce innovative therapies.

For instance, in 2025, Eli Lilly announced a USD 27 billion US manufacturing build-out across multiple sites to expand Eli Lilly GLP-1 supply, addressing increased patient demand and reinforcing market leadership. Collaborative initiatives and ongoing clinical research are also accelerating product development and improving patient access to these therapies, positioning the US as a global GLP-1 receptor agonist market leader.

Asia-Pacific: Driving the Future of Market Expansion

The rapid urbanization and rising middle-class income in key Asia-Pacific countries, such as China, India, and South Korea, are accelerating market growth in the region. Governments are actively supporting disease management through policies while increasing public awareness of GLP-1 benefits and increasing reimbursement schemes.

Pharmaceutical companies are investing heavily to expand manufacturing capacity and introduce innovative therapies, contributing to a significantly higher CAGR compared to other regions. In countries like China and India, the rise of e-commerce platforms and telemedicine also facilitate easier access to GLP-1 treatments.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

GLP-1 Receptor Agonist Market: Report Attributes

Key Report Attribute	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2026	USD 101.4 Billion
Market Size 2035	USD 180 Billion
CAGR (Till 2035)	6.6%
Segments Covered	Type of Molecule Active Compound Used Type of GLP-1 Agonist Drugs GLP-1 Agonist Target Indication Geographical Regions
Key Players Profiled	AstraZeneca Biolingus Boehringer Ingelheim D&D Pharmatech Eli Lilly Gmax Biopharm Hanmi Pharmaceutical Innogen Novo Nordisk PegBio Pfizer QL Biopharma Roche Sanofi Sciwind Biosciences Tonghua Dongbao Pharmaceutical Viking Therapeutics Vivani vTv Therapeutic (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Market Landscape Analysis Partnerships and Collaborations Company Competitiveness Analysis Funding Clinical Trial Analysis Demand Analysis Pricing Analysis Patent Analysis Market Size and Opportunity Analysis

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Overview of the GLP-1 Receptor Agonist

6.2. Mechanism of Action of GLP-1 Receptor Agonist

6.3. Important Facts in GLP-1 Receptor Agonist Domain

6.4. Challenges Associated with GLP-1 Receptor Agonist

6.5. Future Perspectives

+ 7. MARKET LANDSCAPE: GLP-1 RECEPTOR AGONIST

7.1. GLP-1 Receptor Agonist: Market Landscape

7.1.1. Analysis by Status of Development

7.1.2. Analysis by Type of Molecule

7.1.3. Analysis by Active Compound Used

7.1.4. Analysis by Type of Agonist

7.1.5. Analysis by Route of Administration

7.1.6. Analysis by Dosing Frequency

7.1.7. Analysis by Type of Therapy

7.1.8. Analysis by Target Indication

7.1.9. Analysis by Therapeutic Area

7.2. GLP-1 Receptor Agonist: Developer Landscape

7.2.1. Analysis by Year of Establishment

7.2.2. Analysis by Company Size

7.2.3. Analysis by Location of Headquarters

7.2.4. Analysis by Location of Headquarters (Country) and Status of Development

7.2.5. Most Active Developers: Analysis by Number of Therapies

+ 8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview

8.2. Methodology and Key Parameters

8.3. Scoring Criteria

8.4. Overview of Peer Groups

8.5. GLP-1 Receptor Agonist Developers: Company Competitiveness Analysis

8.5.1. GLP-1 Receptor Agonist Developers based in North America (Peer Group I)

8.5.2. GLP-1 Receptor Agonist Developers based in Europe (Peer Group II)

8.5.3. GLP-1 Receptor Agonist Developers in Asia-Pacific and Rest of the World (Peer Group III)

+ 9. GLP-1 RECEPTOR AGONIST: DETAILED COMPANY PROFILES

9.1. Chapter Overview

9.1.1. AstraZeneca

9.1.1.1. Company Overview

9.1.1.2. Pipeline Portfolio

9.1.1.3. Financial Details

9.1.1.4. Recent Developments and Future Outlook

9.1.2. D&D Pharmatech

9.1.3. Eli Lilly

9.1.4. Novo Nordisk

9.1.5. Pfizer

9.1.6. Sanofi

9.1.7. Tonghua Dongbao Pharmaceutical

9.1.8. Vivani

+ 10. GLP-1 RECEPTOR AGONIST: SHORT COMPANY PROFILES

10.1. Chapter Overview

10.1.1. Biolingus

10.1.1.1. Company Overview

10.1.1.2. Pipeline Portfolio

10.1.2. Boehringer Ingelheim

10.1.3. Gmax Biopharm

10.1.4. Hanmi Pharmaceutical

10.1.5. Innogen

10.1.6. PegBio

10.1.7. QL Biopharma

10.1.8. Roche

10.1.9. Sciwind Biosciences

10.1.10. Viking Therapeutics

10.1.11. vTv Therapeutics

+ 11. PARTNERSHIPS AND COLLABORATIONS

11.1. Chapter Overview

11.2. Partnership Models

11.3. GLP-1 Receptor Agonist Developers: List of Partnerships and Collaborations

11.3.1. Analysis by Year of Partnership

11.3.2. Analysis by Type of Partnership

11.3.3. Analysis by Year and Type of Partnership

11.3.4. Analysis by Focus Area

11.3.5. Most Active Players: Analysis by Number of Partnerships

11.3.6. Analysis by Geography

11.3.6.1. Intercontinental and Intracontinental Deals

11.3.6.2. Local and International Deals

+ 12. FUNDING AND INVESTMENTS

12.1. Chapter Overview

12.2. Funding Models

12.3. GLP-1 Receptor Agonist Developers: List of Funding and Investments

12.3.1. Analysis of Funding Instances by Year of Funding

12.3.2. Analysis of Amount Invested by Year of Funding

12.3.3. Analysis by Type of Funding

12.3.4. Analysis by Year and Type of Funding

12.3.5. Analysis by Amount Invested and Type of Funding

12.3.6. Analysis by Purpose of Funding

12.3.7. Analysis by Geography

12.3.8. Most Active Players: Analysis by Number of Instances

12.3.9. Most Active Players: Analysis by Amount Invested

12.3.10. Leading Investors: Analysis by Number of Instances

12.3.11. Funding and Investment Summary

+ 13. CLINICAL TRIAL ANALYSIS

13.1. Chapter Overview

13.2. Scope and Methodology

13.3. GLP-1 Receptor Agonist: Clinical Trial Analysis

13.3.1. Analysis by Trial Registration Year

13.3.2. Analysis of Enrolled Patient Population by Trial Registration Year

13.3.3. Analysis by Trial Status

13.3.4. Analysis of Enrolled Patient Population by Trial Status

13.3.5. Analysis by Trial Registration Year and Trial Status

13.3.6. Analysis by Trial Phase

13.3.7. Analysis of Enrolled Patient Population by Trial Phase

13.3.8. Analysis by Type of Sponsor / Collaborator

13.3.9. Analysis by Study Design

13.3.10. Analysis by Gender

13.3.11. Leading Industry Players: Analysis by Number of Registered Trials

13.3.12. Leading Non-industry Players: Analysis by Number of Registered Trials

13.3.13. Analysis by Trial Status, Trial Phase and Geography

13.3.14. Analysis by Geography

13.3.15. Analysis by Trial Status and Geography

13.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography

+ 14. PATENT ANALYSIS

14.1. Chapter Overview

14.2. Scope and Methodology

14.3. GLP-1 Receptor Agonist: Patent Analysis

14.3.1. Analysis by Patent Publication Year

14.3.2. Analysis by Type of Patent and Publication Year

14.3.3. Analysis by Patent Application Year

14.3.4. Analysis by Patent Jurisdiction

14.3.5. Analysis by CPC Symbols

14.3.6. Analysis by Type of Applicant

14.3.7. Leading Industry Players: Analysis by Number of Patents

14.3.8. Leading Non-Industry Players: Analysis by Number of Patents

14.4. Patent Benchmarking Analysis

14.4.1. Analysis by Patent Characteristics

14.5. Patent Valuation

14.6. Leading Patents by Number of Citations

+ 15. DEMAND ANALYSIS

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.2.1. Global Annual Demand for GLP-1 Receptor Agonist

15.2.1.1. Analysis by Type of Molecule

15.2.1.2. Analysis by Type of Active Compound Used

15.2.1.3. Analysis by Type of GLP-1 Agonist Drugs

15.2.1.4. Analysis by GLP-1 Agonist

15.2.1.5. Analysis by Route of Administration

15.2.1.6. Analysis by Target Indication

15.2.1.7. Analysis by Geography

+ 16. MARKET IMPACT ANALYSIS

16.1. Market Drivers

16.2. Market Restraints

16.3. Market Opportunities

16.4. Market Challenges

+ 17. PRICING ANALYSIS

+ 18. GLOBAL GLP-1 RECEPTOR AGONIST MARKET

18.1. Chapter Overview

18.2. Assumptions and Methodology

18.3. Global GLP-1 Receptor Agonist Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

18.3.1. Roots Analysis Perspective on Market Growth

18.3.2. Scenario Analysis

18.3.2.1. Conservative Scenario

18.3.2.2. Optimistic Scenario

18.4. Key Market Segmentations

+ 19. GLP-1 RECEPTOR AGONIST MARKET, BY TYPE OF MOLECULE

19.1. Chapter Overview

19.2. Assumptions and Methodology

19.3. GLP-1 Receptor Agonist Market: Distribution by Type of Molecule

19.3.1. GLP-1 Receptor Agonist Market for Biologics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.3.2. GLP-1 Receptor Agonist Market for Small Molecules, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.4. Data Triangulation and Validation

+ 20. GLP-1 RECEPTOR AGONIST MARKET, BY ACTIVE COMPOUND USED

20.1. Chapter Overview

20.2. Assumptions and Methodology

20.3. GLP-1 Receptor Agonist Market: Distribution by Active Compound Used

20.3.1. GLP-1 Receptor Agonist Market for Dulaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.2. GLP-1 Receptor Agonist Market for Liraglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.3. GLP-1 Receptor Agonist Market for Orforglipron, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.4. GLP-1 Receptor Agonist Market for Retatrutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.5. GLP-1 Receptor Agonist Market for Semaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.6. GLP-1 Receptor Agonist Market for Survodutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.7. GLP-1 Receptor Agonist Market for Tirzepatide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.3.8. GLP-1 Receptor Agonist Market for Other Active Compounds, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.4. Data Triangulation and Validation

+ 21. GLP-1 RECEPTOR AGONIST MARKET, BY TYPE OF GLP-1 AGONIST DRUGS

21.1. Chapter Overview

21.2. Assumptions and Methodology

21.3. GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs

21.3.1. GLP-1 Receptor Agonist Market for Long-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.3.2. GLP-1 Receptor Agonist Market for Short-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.4. Data Triangulation and Validation

+ 22. GLP-1 RECEPTOR AGONIST MARKET, BY GLP-1 AGONIST

22.1. Chapter Overview

22.2. Assumptions and Methodology

22.3. GLP-1 Receptor Agonist Market: Distribution by GLP-1 Agonist

22.3.1. GLP-1 Receptor Agonist Market for Single-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.3.2. GLP-1 Receptor Agonist Market for Dual-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.3.3. GLP-1 Receptor Agonist Market for Tri-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.4. Data Triangulation and Validation

+ 23. GLP-1 RECEPTOR AGONIST MARKET, BY ROUTE OF ADMINISTRATION

23.1. Chapter Overview

23.2. Assumptions and Methodology

23.3. GLP-1 Receptor Agonist Market: Distribution by Route of Administration

23.3.1. GLP-1 Receptor Agonist Market for Oral route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.3.2. GLP-1 Receptor Agonist Market for Parental Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.4. Data Triangulation and Validation

+ 24. GLP-1 RECEPTOR AGONIST MARKET, BY TARGET INDICATION

24.1. Chapter Overview

24.2. Assumptions and Methodology

24.3. GLP-1 Receptor Agonist Market: Distribution by Target Indication

24.3.1. GLP-1 Receptor Agonist Market for Alzheimer’s Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.3.2. GLP-1 Receptor Agonist Market for Non-Alcoholic Steatohepatitis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.3.3. GLP-1 Receptor Agonist Market for Obesity, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.3.4. GLP-1 Receptor Agonist Market for Sleep Apnea, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.3.5. GLP-1 Receptor Agonist Market for Type 2 Diabetes, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.4. Data Triangulation and Validation

+ 25. GLP-1 RECEPTOR AGONIST MARKET, BY GEOGRAPHICAL REGIONS

25.1. Chapter Overview

25.2. Assumptions and Methodology

25.3. GLP-1 Receptor Agonist Market: Distribution by Geographical Regions

25.3.1. GLP-1 Receptor Agonist Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.1.1. GLP-1 Receptor Agonist Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.1.2. GLP-1 Receptor Agonist Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2. GLP-1 Receptor Agonist Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2.1. GLP-1 Receptor Agonist Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2.2. GLP-1 Receptor Agonist Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2.3. GLP-1 Receptor Agonist Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2.4. GLP-1 Receptor Agonist Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2.5. GLP-1 Receptor Agonist Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.2.6. GLP-1 Receptor Agonist Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.3. GLP-1 Receptor Agonist Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.3.1. GLP-1 Receptor Agonist Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.3.2. GLP-1 Receptor Agonist Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.3.3. GLP-1 Receptor Agonist Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.3.4. GLP-1 Receptor Agonist Market in Australia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.3.5. GLP-1 Receptor Agonist Market in Rest of Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.4. GLP-1 Receptor Agonist Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.4.1. GLP-1 Receptor Agonist Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.4.2. GLP-1 Receptor Agonist Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.3.4.3. GLP-1 Receptor Agonist Market in Rest of Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.4. Data Triangulation and Validation

+ 26. GLP-1 RECEPTOR AGONIST MARKET, SALES FORECAST OF GLP-1 DRUGS

26.1. Chapter Overview

26.1.1. Assumptions and Methodology

26.2. Approved GLP-1 Drugs: Sales Forecast

26.2.1. Feisumei (Benaglutide) Sales Forecast

26.2.2. Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast

26.2.3. Mounjaro (Tirzepatide) Sales Forecast

26.2.4. Ozempic (Semaglutide Subcutaneous) Sales Forecast

26.2.5. Rybelsus (Semaglutide Oral) Sales Forecast

26.2.6. Saxenda (Liraglutide) Sales Forecast

26.2.7. Trulicity (Dulaglutide) Sales Forecast

26.2.8. Victoza (Liraglutide) Sales Forecast

26.2.9. Wegovy (Semaglutide Subcutaneous) Sales Forecast

26.2.10. XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast

26.2.11. Zepbound (Tirzepatide) Sales Forecast

26.3. Phase III GLP-1 Drugs: Sales Forecast

26.3.1. GMA102 / Glutazumab Sales Forecast

26.3.2. JY09 Sales Forecast

26.3.3. LY3298176 / Tirzepatide Sales Forecast

26.3.4. Mazdutide / LY3305677/ IBI-362 Sales Forecast

26.3.5. Orforglipron / LY3502970 Sales Forecast

26.3.6. PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast

26.3.7. Retatrutide / LY3437943 Sales Forecast

26.3.8. Semaglutide Oral Sales Forecast

26.3.9. Semaglutide Subcutaneous Sales Forecast

26.3.10. Survodutide / BI 456906 Sales Forecast

26.3.11. XW003 / Ecnoglutide Sales Forecast

26.3.12. YN011-isupaglutide Sales Forecast

+ 27. GLP-1 RECEPTOR AGONIST MARKET, BY LEADING DRUG DEVELOPERS

27.1. Chapter Overview

27.2. Assumptions and Methodology

27.3. GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers, 2020 (USD Million)

27.4. GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers, Current Year (USD Million)

27.5. GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers, 2035 (USD Million)

+ 28. GLP-1 RECEPTOR AGONIST MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

28.1. GLP-1 Receptor Agonist Market in North America: Distribution by Type of Molecule

28.1.1. GLP-1 Receptor Agonist Market in North America for Biologics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.1.2. GLP-1 Receptor Agonist Market in North America for Small Molecules, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2. GLP-1 Receptor Agonist Market in North America: Distribution by Active Compound Used

28.2.1. GLP-1 Receptor Agonist Market in North America for Dulaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.2. GLP-1 Receptor Agonist Market in North America for Liraglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.3. GLP-1 Receptor Agonist Market in North America for Orforglipron, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.4. GLP-1 Receptor Agonist Market in North America for Retatrutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.5. GLP-1 Receptor Agonist Market in North America for Semaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.6. GLP-1 Receptor Agonist Market in North America for Survodutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.7. GLP-1 Receptor Agonist Market in North America for Tirzepatide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.2.8. GLP-1 Receptor Agonist Market in North America for Other Active Compounds, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.3. GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs

28.3.1. GLP-1 Receptor Agonist Market in North America for Long-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.3.2. GLP-1 Receptor Agonist Market in North America for Short-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.4. GLP-1 Receptor Agonist Market in North America: Distribution by GLP-1 Agonist

28.4.1. GLP-1 Receptor Agonist Market in North America for Single-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.4.2. GLP-1 Receptor Agonist Market in North America for Dual-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.4.3. GLP-1 Receptor Agonist Market in North America for Tri-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.5. GLP-1 Receptor Agonist Market in North America: Distribution by Route of Administration

28.5.1. GLP-1 Receptor Agonist Market in North America for Oral route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.5.2. GLP-1 Receptor Agonist Market in North America for Parental Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6. GLP-1 Receptor Agonist Market in North America: Distribution by Target Indication

28.6.1. GLP-1 Receptor Agonist Market in North America for Alzheimer’s Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.2. GLP-1 Receptor Agonist Market in North America for Non-Alcoholic Steatohepatitis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.3. GLP-1 Receptor Agonist Market in North America for Obesity, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.4. GLP-1 Receptor Agonist Market in North America for Sleep Apnea, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.6.5. GLP-1 Receptor Agonist Market in North America for Type 2 Diabetes, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

+ 29. GLP-1 RECEPTOR AGONIST MARKET OPPORTUNITY ANALYSIS: EUROPE

29.1. GLP-1 Receptor Agonist Market in Europe: Distribution by Type of Molecule

29.1.1. GLP-1 Receptor Agonist Market in Europe for Biologics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.1.2. GLP-1 Receptor Agonist Market in Europe for Small Molecules, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2. GLP-1 Receptor Agonist Market in Europe: Distribution by Active Compound Used

29.2.1. GLP-1 Receptor Agonist Market in Europe for Dulaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.2. GLP-1 Receptor Agonist Market in Europe for Liraglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.3. GLP-1 Receptor Agonist Market in Europe for Orforglipron, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.4. GLP-1 Receptor Agonist Market in Europe for Retatrutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.5. GLP-1 Receptor Agonist Market in Europe for Semaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.6. GLP-1 Receptor Agonist Market in Europe for Survodutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.7. GLP-1 Receptor Agonist Market in Europe for Tirzepatide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.2.8. GLP-1 Receptor Agonist Market in Europe for Other Active Compounds, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.3. GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs

29.3.1. GLP-1 Receptor Agonist Market in Europe for Long-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.3.2. GLP-1 Receptor Agonist Market in Europe for Short-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.4. GLP-1 Receptor Agonist Market in Europe: Distribution by GLP-1 Agonist

29.4.1. GLP-1 Receptor Agonist Market in Europe for Single-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.4.2. GLP-1 Receptor Agonist Market in Europe for Dual-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.4.3. GLP-1 Receptor Agonist Market in Europe for Tri-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.5. GLP-1 Receptor Agonist Market in Europe: Distribution by Route of Administration

29.5.1. GLP-1 Receptor Agonist Market in Europe for Oral route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.5.2. GLP-1 Receptor Agonist Market in Europe for Parental Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6. GLP-1 Receptor Agonist Market in Europe: Distribution by Target Indication

29.6.1. GLP-1 Receptor Agonist Market in Europe for Alzheimer’s Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6.2. GLP-1 Receptor Agonist Market in Europe for Non-Alcoholic Steatohepatitis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6.3. GLP-1 Receptor Agonist Market in Europe for Obesity, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6.4. GLP-1 Receptor Agonist Market in Europe for Sleep Apnea, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.6.5. GLP-1 Receptor Agonist Market in Europe for Type 2 Diabetes, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

+ 30. GLP-1 RECEPTOR AGONIST MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

30.1. GLP-1 Receptor Agonist Market in Asia-Pacific: Distribution by Type of Molecule

30.1.1. GLP-1 Receptor Agonist Market in Asia-Pacific for Biologics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.1.2. GLP-1 Receptor Agonist Market in Asia-Pacific for Small Molecules, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2. GLP-1 Receptor Agonist Market in Asia-Pacific: Distribution by Active Compound Used

30.2.1. GLP-1 Receptor Agonist Market in Asia-Pacific for Dulaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.2. GLP-1 Receptor Agonist Market in Asia-Pacific for Liraglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.3. GLP-1 Receptor Agonist Market in Asia-Pacific for Orforglipron, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.4. GLP-1 Receptor Agonist Market in Asia-Pacific for Retatrutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.5. GLP-1 Receptor Agonist Market in Asia-Pacific for Semaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.6. GLP-1 Receptor Agonist Market in Asia-Pacific for Survodutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.7. GLP-1 Receptor Agonist Market in Asia-Pacific for Tirzepatide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.2.8. GLP-1 Receptor Agonist Market in Asia-Pacific for Other Active Compounds, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.3. GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs

30.3.1. GLP-1 Receptor Agonist Market in Asia-Pacific for Long-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.3.2. GLP-1 Receptor Agonist Market in Asia-Pacific for Short-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.4. GLP-1 Receptor Agonist Market in Asia-Pacific: Distribution by GLP-1 Agonist

30.4.1. GLP-1 Receptor Agonist Market in Asia-Pacific for Single-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.4.2. GLP-1 Receptor Agonist Market in Asia-Pacific for Dual-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.4.3. GLP-1 Receptor Agonist Market in Asia-Pacific for Tri-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.5. GLP-1 Receptor Agonist Market in Asia-Pacific: Distribution by Route of Administration

30.5.1. GLP-1 Receptor Agonist Market in Asia-Pacific for Oral route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.5.2. GLP-1 Receptor Agonist Market in Asia-Pacific for Parental Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.6. GLP-1 Receptor Agonist Market in Asia-Pacific: Distribution by Target Indication

30.6.1. GLP-1 Receptor Agonist Market in Asia-Pacific for Alzheimer’s Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.6.2. GLP-1 Receptor Agonist Market in Asia-Pacific for Non-Alcoholic Steatohepatitis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.6.3. GLP-1 Receptor Agonist Market in Asia-Pacific for Obesity, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.6.4. GLP-1 Receptor Agonist Market in Asia-Pacific for Sleep Apnea, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.6.5. GLP-1 Receptor Agonist Market in Asia-Pacific for Type 2 Diabetes, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

+ 31. GLP-1 RECEPTOR AGONIST MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

31.1. GLP-1 Receptor Agonist Market in Latin America: Distribution by Type of Molecule

31.1.1. GLP-1 Receptor Agonist Market in Latin America for Biologics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.1.2. GLP-1 Receptor Agonist Market in Latin America for Small Molecules, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2. GLP-1 Receptor Agonist Market in Latin America: Distribution by Active Compound Used

31.2.1. GLP-1 Receptor Agonist Market in Latin America for Dulaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.2. GLP-1 Receptor Agonist Market in Latin America for Liraglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.3. GLP-1 Receptor Agonist Market in Latin America for Orforglipron, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.4. GLP-1 Receptor Agonist Market in Latin America for Retatrutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.5. GLP-1 Receptor Agonist Market in Latin America for Semaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.6. GLP-1 Receptor Agonist Market in Latin America for Survodutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.7. GLP-1 Receptor Agonist Market in Latin America for Tirzepatide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.2.8. GLP-1 Receptor Agonist Market in Latin America for Other Active Compounds, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.3. GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs

31.3.1. GLP-1 Receptor Agonist Market in Latin America for Long-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.3.2. GLP-1 Receptor Agonist Market in Latin America for Short-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.4. GLP-1 Receptor Agonist Market in Latin America: Distribution by GLP-1 Agonist

31.4.1. GLP-1 Receptor Agonist Market in Latin America for Single-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.4.2. GLP-1 Receptor Agonist Market in Latin America for Dual-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.4.3. GLP-1 Receptor Agonist Market in Latin America for Tri-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.5. GLP-1 Receptor Agonist Market in Latin America: Distribution by Route of Administration

31.5.1. GLP-1 Receptor Agonist Market in Latin America for Oral route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.5.2. GLP-1 Receptor Agonist Market in Latin America for Parental Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.6. GLP-1 Receptor Agonist Market in Latin America: Distribution by Target Indication

31.6.1. GLP-1 Receptor Agonist Market in Latin America for Alzheimer’s Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.6.2. GLP-1 Receptor Agonist Market in Latin America for Non-Alcoholic Steatohepatitis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.6.3. GLP-1 Receptor Agonist Market in Latin America for Obesity, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.6.4. GLP-1 Receptor Agonist Market in Latin America for Sleep Apnea, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

31.6.5. GLP-1 Receptor Agonist Market in Latin America for Type 2 Diabetes, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

**Detailed information on Chapter 28 to 31 is available in the Excel Data Packs shared along with the report**

+ 32. CONCLUDING REMARKS

+ 33. EXECUTIVE INSIGHTS

33.1. Chapter Overview

33.2. Company A

33.2.1. Company Snapshot

33.2.2. Interview Transcript: Chief Executive Officer, Very Large Organization

33.3. Company B

33.3.1. Company Snapshot

33.3.2. Interview Transcript: Associate Professor, Large Organization

33.4. Company C

33.4.1. Company Snapshot

33.4.2. Interview Transcript: Chief Scientific Officer, Mid-sized Organization

33.5. Company D

33.5.1. Company Snapshot

33.5.2. Interview Transcript: chief Commercial Officer, Mid-sized Organization

33.6. Company E

33.6.1. Company Snapshot

33.6.2. Interview Transcript: Senior Account Executive, Large Organization

33.7. Company F

33.7.1. Company Snapshot

33.7.2. Interview Transcript: Chief Executive Officer, Large Organization

33.8. Company G

33.8.1. Company Snapshot

33.8.2. Interview Transcript: Chief Executive Officer, Large Organization

33.9. Company H

33.9.1. Company Snapshot

33.9.2. Interview Transcript: Chief Scientific Advisor for Research, Large Organization

33.10. Company I

33.10.1. Company Snapshot

33.10.2. Interview Transcript: Chief Executive Officer, Mid-sized Organization

33.11. Company J

33.11.1. Company Snapshot

33.11.2. Interview Transcript: Chief Medical Officer, Mid-sized Organization

+ 34. APPENDIX I: TABULATED DATA

+ 35. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Market Assessment Framework

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Advantage of GLP-1 Drugs

Figure 6.2 Challenges Associated with GLP-1 Receptor Agonist

Figure 6.3 Mechanisms of Action of GLP-1 Receptor Agonist

Figure 7.1 GLP-1 Receptor Agonist: Distribution by Status of Development

Figure 7.2 GLP-1 Receptor Agonist: Distribution by Type of Molecule

Figure 7.3 GLP-1 Receptor Agonist: Distribution by Active Compound Used

Figure 7.4 GLP-1 Receptor Agonist: Distribution by Type of Agonist

Figure 7.5 GLP-1 Receptor Agonist: Distribution by Route of Administration

Figure 7.6 GLP-1 Receptor Agonist: Distribution by Dosing Frequency

Figure 7.7 GLP-1 Receptor Agonist: Distribution by Type of Therapy

Figure 7.8 GLP-1 Receptor Agonist: Distribution by Target Indication

Figure 7.9 GLP-1 Receptor Agonist: Distribution by Therapeutic Area

Figure 7.10 GLP-1 Receptor Agonist Developer: Distribution by Year of Establishment

Figure 7.11 GLP-1 Receptor Agonist Developer: Distribution by Company Size

Figure 7.12 GLP-1 Receptor Agonist Developer: Distribution by Location of Headquarters

Figure 7.13 GLP-1 Receptor Agonist Developer: Distribution by Location of Headquarters (Country) and Status of Development

Figure 7.14 Most Active Developers: Distribution by Number of Drugs

Figure 8.1 Company Competitiveness Analysis: GLP-1 Receptor Agonist Developers based in North America

Figure 8.2 Company Competitiveness Analysis: GLP-1 Receptor Agonist Developers based in Europe

Figure 8.3 Company Competitiveness Analysis: GLP-1 Receptor Agonist Developers based in Asia-Pacific and Rest of the World

Figure 9.1 AstraZeneca: Annual Revenues, Since FY 2021 (USD Billion)

Figure 9.2 D&D Pharmatech: Annual Revenues, Since FY 2021 (Korean Won Billion)

Figure 9.3 Eli Lilly: Annual Revenues, Since FY 2021 (USD Billion)

Figure 9.4 Novo Nordisk: Annual Revenues, Since FY 2021 (DKK Billion)

Figure 9.5 Pfizer: Annual Revenues, Since FY 2021 (USD Billion)

Figure 9.6 Sanofi: Annual Revenues, Since FY 2021 (EUR Billion)

Figure 9.7 Tonghua Dongbao Pharmaceutical: Annual Revenues, Since FY 2021 (RMB Billion)

Figure 9.8 Vivani: Annual Revenues, Since FY 2021 (RMB Billion)

Figure 11.1 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2022

Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 11.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership

Figure 11.4 Partnerships and Collaborations: Distribution by Focus Area

Figure 11.5 Most Active Players: Distribution by Number of Partnerships

Figure 11.6 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals

Figure 11.7 Partnerships and Collaborations: Distribution by Local and International Deals

Figure 12.1 Funding and Investments: Cumulative Year-wise Distribution of Funding Instances, Since 2021

Figure 12.2 Funding and Investments: Cumulative Year-wise Distribution of Amount Invested (USD Million), Since 2021

Figure 12.3 Funding and Investments: Distribution by Year of Funding and Amount Invested (USD Million), Since 2021

Figure 12.4 Funding and Investments: Distribution by Type of Funding

Figure 12.5 Funding and Investments: Distribution by Year and Type of Funding, Since 2021

Figure 12.6 Funding and Investments: Distribution by Amount Invested and Type of Funding

Figure 12.7 Funding and Investments: Distribution by Purpose of Funding

Figure 12.8 Funding and Investments: Distribution by Geography

Figure 12.9 Most Active Players: Distribution by Number of Instances

Figure 12.10 Most Active Players: Distribution by Amount Invested (USD Million)

Figure 12.11 Leading Investors: Distribution by Number of Funding Instances

Figure 12.12 Funding and Investment Summary, Since 2021

Figure 13.1 Distribution by Trial Registration Year, Since 2021

Figure 13.2 Distribution of Enrolled Patient Population by Trial Registration Year

Figure 13.3 Distribution by Trial Status

Figure 13.4 Distribution of Enrolled Patient Population by Trial Status

Figure 13.5 Distribution by Trial Registration Year and Trial Status

Figure 13.6 Distribution by Trial Phase

Figure 13.7 Distribution of Enrolled Patient Population by Trial Phase

Figure 13.8 Distribution by Type of Sponsor / Collaborator

Figure 13.9 Distribution by Study Design

Figure 13.10 Distribution by Gender

Figure 13.11 Leading Industry Players: Distribution by Number of Registered Trials

Figure 13.12 Leading Non-industry Players: Distribution by Number of Registered Trials

Figure 13.13 Distribution of by Trial Status, Trial Phase and Geography

Figure 13.14 Distribution by Geography

Figure 13.15 Distribution by Trial Status and Geography

Figure 13.16 Distribution of Enrolled Patient Population by Trial Status and Geography

Figure 14.1 Patent Analysis: Distribution by Type of Patent

Figure 14.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2021

Figure 14.3 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2021

Figure 14.4 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019

Figure 14.5 Patent Analysis: Patent Jurisdiction

Figure 14.6 Patent Analysis: Distribution by CPC Symbols

Figure 14.7 Leading Industry Players: Distribution by Number of Patents

Figure 14.8 Leading Non-Industry Players: Distribution by Number of Patents

Figure 14.9 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players

Figure 14.10 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)

Figure 14.11 Patent Analysis: Distribution by Patent Age

Figure 14.12 GLP-1 Receptor Agonist: Patent Valuation

Figure 15.1 Global Annual Demand for GLP-1 Drugs, Since 2020 (in units)

Figure 15.2 Global Demand for GLP-1 Receptor Agonist: Distribution by Type of Molecule (in units)

Figure 15.3 Global Demand for GLP-1 Receptor Agonist: Distribution by Type of Active Compound Used (in units)

Figure 15.4 Global Demand for GLP-1 Receptor Agonist: Distribution by Type of GLP-1 Agonist Drugs (in units)

Figure 15.5 Global Demand for GLP-1 Receptor Agonist: Distribution by GLP-1 Agonist (in units)

Figure 15.6 Global Demand for GLP-1 Receptor Agonist: Distribution by Route of Administration (in units)

Figure 15.7 Global Demand for GLP-1 Receptor Agonist: Distribution by Target Indication (in units)

Figure 15.8 Global Demand for GLP-1 Receptor Agonist: Distribution by Geography (in units)

Figure 18.1 Global GLP-1 Receptor Agonist Market, Historical Trends (since 2020) and Forecasted Estimates (Till 2035)

Figure 18.2 Global GLP-1 Receptor Agonist Market, Forecasted Estimates (Till 2035): Conservative Scenario

Figure 18.3 Global GLP-1 Receptor Agonist Market, Forecasted Estimates (Till 2035): Optimistic Scenario

Figure 19.1 GLP-1 Receptor Agonist Market: Distribution by Type of Molecule, 2020, Current Year and 2035

Figure 19.2 GLP-1 Receptor Agonist Market for Biologics, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 19.3 GLP-1 Receptor Agonist Market for Small Molecules, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.1 GLP-1 Receptor Agonist Market: Distribution by Type of Active Compound Used, 2020, Current Year and 2035

Figure 20.2 GLP-1 Receptor Agonist Market for Dulaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.3 GLP-1 Receptor Agonist Market for Liraglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.4 GLP-1 Receptor Agonist Market for Orforglipron, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.5 GLP-1 Receptor Agonist Market for Retatrutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.6 GLP-1 Receptor Agonist Market for Semaglutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.7 GLP-1 Receptor Agonist Market for Survodutide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.8 GLP-1 Receptor Agonist Market for Tirzepatide, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 20.9 GLP-1 Receptor Agonist Market for Other Active Compounds, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 21.1 GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs, 2020, Current Year and 2035

Figure 21.2 GLP-1 Receptor Agonist Market for Long-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 21.3 GLP-1 Receptor Agonist Market for Short-acting GLP-1 Agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 22.1 GLP-1 Receptor Agonist Market: Distribution by GLP-1 Agonist, 2020, Current Year and 2035

Figure 22.2 GLP-1 Receptor Agonist Market for Single-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 22.3 GLP-1 Receptor Agonist Market for Dual-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 22.4 GLP-1 Receptor Agonist Market for Tri-agonist, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 23.1 GLP-1 Receptor Agonist Market: Distribution by Route of Administration, 2020, Current Year and 2035

Figure 23.2 GLP-1 Receptor Agonist Market for Oral Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 23.3 GLP-1 Receptor Agonist Market for Parental Route, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 24.1 GLP-1 Receptor Agonist Market: Distribution by Target Indication, 2020, Current Year and 2035

Figure 24.2 GLP-1 Receptor Agonist Market for Alzheimer’s Disease, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 24.3 GLP-1 Receptor Agonist Market for Non-Alcoholic Steatohepatitis, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 24.4 GLP-1 Receptor Agonist Market for Obesity, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 24.5 GLP-1 Receptor Agonist Market for Sleep Apnea, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 24.6 GLP-1 Receptor Agonist Market for Type 2 Diabetes, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.1 GLP-1 Receptor Agonist Market: Distribution by Geographical Regions, 2020, Current Year and 2035

Figure 25.2 GLP-1 Receptor Agonist Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

Figure 25.3 GLP-1 Receptor Agonist Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.4 GLP-1 Receptor Agonist Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.5 GLP-1 Receptor Agonist Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.6 GLP-1 Receptor Agonist Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.7 GLP-1 Receptor Agonist Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.8 GLP-1 Receptor Agonist Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.9 GLP-1 Receptor Agonist Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.10 GLP-1 Receptor Agonist Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.11 GLP-1 Receptor Agonist Market in Rest of Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.12 GLP-1 Receptor Agonist Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.13 GLP-1 Receptor Agonist Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.14 GLP-1 Receptor Agonist Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.15 GLP-1 Receptor Agonist Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.16 GLP-1 Receptor Agonist Market in Australia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.17 GLP-1 Receptor Agonist Market in Rest of Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.18 GLP-1 Receptor Agonist Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.19 GLP-1 Receptor Agonist Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.20 GLP-1 Receptor Agonist Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 25.21 GLP-1 Receptor Agonist Market in Rest of Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

Figure 26.1 Approved GLP-1 Receptor Agonist Drug, Feisumei (Benaglutide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.2 Approved GLP-1 Receptor Agonist Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.3 Approved GLP-1 Receptor Agonist Drug, Mounjaro (Tirzepatide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.4 Approved GLP-1 Receptor Agonist Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, Till 2035 (USD Billion)

Figure 26.5 Approved GLP-1 Receptor Agonist Drug, Rybelsus (Semaglutide Oral) Sales Forecast, Till 2035 (USD Billion)

Figure 26.6 Approved GLP-1 Receptor Agonist Drug, Saxenda (Liraglutide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.7 Approved GLP-1 Receptor Agonist Drug, Trulicity (Dulaglutide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.8 Approved GLP-1 Receptor Agonist Drug, Victoza (Liraglutide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.9 Approved GLP-1 Receptor Agonist Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, Till 2035 (USD Billion)

Figure 26.10 Approved GLP-1 Receptor Agonist Drug, XULTOPHY (Insulin Degludec / Liraglutide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.11 Approved GLP-1 Receptor Agonist Drug, Zepbound (Tirzepatide) Sales Forecast, Till 2035 (USD Billion)

Figure 26.12 Phase III GLP-1 Receptor Agonist Drug, GMA102 / Glutazumab Sales Forecast, Till 2035 (USD Billion)

Figure 26.13 Phase III GLP-1 Receptor Agonist Drug, JY09 Sales Forecast, Till 2035 (USD Billion)

Figure 26.14 Phase III GLP-1 Receptor Agonist Drug, LY3298176 / Tirzepatide Sales Forecast, Till 2035 (USD Billion)

Figure 26.15 Phase III GLP-1 Receptor Agonist Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, Till 2035 (USD Billion)

Figure 26.16 Phase III GLP-1 Receptor Agonist Drug, Orforglipron / LY3502970 Sales Forecast, Till 2035 (USD Billion)

Figure 26.17 Phase III GLP-1 Receptor Agonist Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, Till 2035 (USD Billion)

Figure 26.18 Phase III GLP-1 Receptor Agonist Drug, Retatrutide / LY3437943 Sales Forecast, Till 2035 (USD Billion)

Figure 26.19 Phase III GLP-1 Receptor Agonist Drug, Semaglutide Oral Sales Forecast, Till 2035 (USD Billion)

Figure 26.20 Phase III GLP-1 Receptor Agonist Drug, Semaglutide Subcutaneous Sales Forecast, Till 2035 (USD Billion)

Figure 26.21 Phase III GLP-1 Receptor Agonist Drug, Survodutide / BI 456906 Sales Forecast, Till 2035 (USD Billion)

Figure 26.22 Phase III GLP-1 Receptor Agonist Drug, XW003 / Ecnoglutide Sales Forecast, Till 2035 (USD Billion)

Figure 26.23 Phase III GLP-1 Receptor Agonist Drug, YN011-isupaglutide Sales Forecast, Till 2035 (USD Billion)

Figure 27.1 GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020 (USD Billion))

Figure 27.2 GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in the Current Year (USD Billion))

Figure 27.3 GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035 (USD Billion))

+ List of Tables

Table 7.1 List of GLP-1 Receptor Agonists

Table 7.2 List of GLP-1 Receptor Agonist Developers

Table 9.1 AstraZeneca: Pipeline Portfolio

Table 9.2 AstraZeneca: Recent Developments and Future Outlook

Table 9.3 D&D Pharmatech: Pipeline Portfolio

Table 9.4 D&D Pharmatech: Recent Developments and Future Outlook

Table 9.5 Eli Lilly: Pipeline Portfolio

Table 9.6 Eli Lilly: Recent Developments and Future Outlook

Table 9.7 Novo Nordisk: Pipeline Portfolio

Table 9.8 Novo Nordisk: Recent Developments and Future Outlook

Table 9.9 Pfizer: Pipeline Portfolio

Table 9.10 Pfizer: Recent Developments and Future Outlook

Table 9.11 Sanofi: Pipeline Portfolio

Table 9.12 Sanofi: Recent Developments and Future Outlook

Table 9.13 Tonghua Dongbao Pharmaceutical: Pipeline Portfolio

Table 9.14 Tonghua Dongbao Pharmaceutical: Recent Developments and Future Outlook

Table 9.15 Vivani: Pipeline Portfolio

Table 9.16 Vivani: Recent Developments and Future Outlook

Table 10.1 Biolingus: Pipeline Portfolio

Table 10.2 Boehringer Ingelheim: Pipeline Portfolio

Table 10.3 Gmax Biopharm: Pipeline Portfolio

Table 10.4 Hanmi Pharmaceutical: Pipeline Portfolio

Table 10.5 PegBio: Pipeline Portfolio

Table 10.6 QL Biopharma: Pipeline Portfolio

Table 10.7 Roche: Pipeline Portfolio

Table 10.8 Sciwind Biosciences: Pipeline Portfolio

Table 10.9 Viking Therapeutics: Pipeline Portfolio

Table 10.10 vTv Therapeutics: Pipeline Portfolio

Table 11.1 GLP-1 Receptor Agonist Market: List of Partnerships and Collaborations, Since 2021

Table 12.1 GLP-1 Receptor Agonist Market: List of Funding and Investments, Since 2021

Table 14.1 Patent Analysis: Top CPC Sections

Table 14.2 Patent Analysis: Top CPC Symbols

Table 14.3 Patent Analysis: Top CPC Codes

Table 14.4 Patent Analysis: Summary of Benchmarking Analysis

Table 14.5 Patent Analysis: Categorization based on Weighted Valuation Scores

Table 14.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)

Table 14.7 Patent Portfolio: List of Leading Patents (by Number of Citations)

Table 18.1 List of GLP-1 Receptor Agonist Drugs Forecasted

Table 34.1 GLP-1 Receptor Agonist Drug: Distribution by Status of Development

Table 34.2 GLP-1 Receptor Agonist Drug: Distribution by Type of Molecule

Table 34.3 GLP-1 Receptor Agonist Drug: Distribution by Active Compound Used

Table 34.4 GLP-1 Receptor Agonist Drug: Distribution by Type of Agonist

Table 34.5 GLP-1 Receptor Agonist Drug: Distribution by Route of Administration

Table 34.6 GLP-1 Receptor Agonist Drug: Distribution by Dosing Frequency

Table 34.7 GLP-1 Receptor Agonist Drug: Distribution by Type of Therapy

Table 34.8 GLP-1 Receptor Agonist Drug: Distribution by Target Indication

Table 34.9 GLP-1 Receptor Agonist Drug: Distribution by Therapeutic Area

Table 34.10 GLP-1 Receptor Agonist Developer: Distribution by Year of Establishment

Table 34.11 GLP-1 Receptor Agonist Developer: Distribution by Company Size

Table 34.12 GLP-1 Receptor Agonist Developer: Distribution by Location of Headquarters

Table 34.13 GLP-1 Drugs Developer: Distribution by Location of Headquarters (Country) and Status of Development

Table 34.14 Most Active Developers: Distribution by Number of GLP-1 Receptor Agonist Drugs

Table 34.15 AstraZeneca: Annual Revenues, Since FY 2021 (USD Billion)

Table 34.16 D&D Pharmatech: Annual Revenues, Since FY 2021 (Korean Won Billion)

Table 34.17 Eli Lilly: Annual Revenues, Since FY 2021 (USD Billion)

Table 34.18 Novo Nordisk: Annual Revenues, Since FY 2021 (DKK Billion)

Table 34.19 Pfizer: Annual Revenues, Since FY 2021 (USD Billion)

Table 34.20 Sanofi: Annual Revenues, Since FY 2021 (EUR Billion)

Table 34.21 Tonghua Dongbao Pharmaceutical: Annual Revenues, Since FY 2021 (RMB Billion)

Table 34.22 Vivani: Annual Revenues, Since FY 2021 (RMB Billion)

Table 34.23 Partnerships and Collaborations: Distribution by Year of Partnership, Since 2022

Table 34.24 Partnerships and Collaborations: Distribution by Type of Partnership

Table 34.25 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership

Table 34.26 Partnerships and Collaborations: Distribution by Focus Area

Table 34.27 Most Active Players: Distribution by Number of Partnerships

Table 34.28 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Deals

Table 34.29 Partnerships and Collaborations: Distribution by Local and International Deals

Table 34.30 Funding and Investments: Cumulative Year-wise Distribution of Funding Instances, Since 2021

Table 34.31 Funding and Investments: Cumulative Year-wise Distribution of Amount Invested (USD Million), Since 2021

Table 34.32 Funding and Investments: Distribution by Year of Funding and Amount Invested (USD Million), Since 2021

Table 34.33 Funding and Investments: Distribution by Type of Funding

Table 34.34 Funding and Investments: Distribution by Year and Type of Funding, Since 2021

Table 34.35 Funding and Investments: Distribution by Amount Invested and Type of Funding

Table 34.36 Funding and Investments: Distribution by Purpose of Funding

Table 34.37 Funding and Investments: Distribution by Geography

Table 34.38 Most Active Players: Distribution by Number of Instances

Table 34.39 Most Active Players: Distribution by Amount Invested (USD Million)

Table 34.40 Leading Investors: Distribution by Number of Funding Instances

Table 34.41 Funding and Investment Summary, Since 2021

Table 34.42 Distribution by Trial Registration Year, Since 2021

Table 34.43 Distribution of Enrolled Patient Population by Trial Registration Year

Table 34.44 Distribution by Trial Status

Table 34.45 Distribution of Enrolled Patient Population by Trial Status

Table 34.46 Distribution by Trial Registration Year and Trial Status

Table 34.47 Distribution by Trial Phase

Table 34.48 Distribution of Enrolled Patient Population by Trial Phase

Table 34.49 Distribution by Type of Sponsor / Collaborator

Table 34.50 Distribution by Study Design

Table 34.51 Distribution by Gender

Table 34.52 Leading Industry Players: Distribution by Number of Registered Trials

Table 34.53 Leading Non-industry Players: Distribution by Number of Registered Trials

Table 34.54 Distribution of by Trial Status, Trial Phase and Geography

Table 34.55 Distribution by Geography

Table 34.56 Distribution by Trial Status and Geography

Table 34.57 Distribution of Enrolled Patient Population by Trial Status and Geography

Table 34.58 Patent Analysis: Distribution by Type of Patent

Table 34.59 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2021

Table 34.60 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2021

Table 34.61 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019

Table 34.62 Patent Analysis: Patent Jurisdiction

Table 34.63 Leading Industry Players: Distribution by Number of Patents

Table 34.64 Leading Non-Industry Players: Distribution by Number of Patents

Table 34.65 Patent Analysis: Distribution by Patent Age

Table 34.66 GLP-1: Patent Valuation

Table 34.67 Global Annual Demand for GLP-1 Drugs, Since 2020 (in units)

Table 34.68 Global Demand for GLP-1 Receptor Agonist: Distribution by Type of Molecule (in units)

Table 34.69 Global Demand for GLP-1 Receptor Agonist: Distribution by Type of Active Compound Used (in units)

Table 34.70 Global Demand for GLP-1 Receptor Agonist: Distribution by Type of GLP-1 Agonist Drugs (in units)

Table 34.71 Global Demand for GLP-1 Receptor Agonist: Distribution by GLP-1 Agonist (in units)

Table 34.72 Global Demand for GLP-1 Receptor Agonist: Distribution by Route of Administration (in units)

Table 34.73 Global Demand for GLP-1 Receptor Agonist: Distribution by Target Indication (in units)

Table 34.74 Global Demand for GLP-1 Receptor Agonist: Distribution by Geography (in units)

Table 34.75 Global GLP-1 Receptor Agonist Market, Historical Trends (since 2020) and Forecasted Estimates (Till 2035)

Table 34.76 Global GLP-1 Receptor Agonist Market, Forecasted Estimates (Till 2035): Conservative Scenario

Table 34.77 Global GLP-1 Receptor Agonist Market, Forecasted Estimates (Till 2035): Optimistic Scenario

Table 34.78 GLP-1 Receptor Agonist Market: Distribution by Type of Molecule, 2020, Current Year and 2035

Table 34.79 GLP-1 Receptor Agonist Market for Biologics, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.80 GLP-1 Receptor Agonist Market for Small Molecules, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.81 GLP-1 Receptor Agonist Market: Distribution by Type of Active Compound Used, 2020, Current Year and 2035

Table 34.82 GLP-1 Receptor Agonist Market for Dulaglutide, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.83 GLP-1 Receptor Agonist Market for Liraglutide, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.84 GLP-1 Receptor Agonist Market for Orforglipron, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.85 GLP-1 Receptor Agonist Market for Retatrutide, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.86 GLP-1 Receptor Agonist Market for Semaglutide, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.87 GLP-1 Receptor Agonist Market for Survodutide, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.88 GLP-1 Receptor Agonist Market for Tirzepatide, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.89 GLP-1 Receptor Agonist Market for Other Active Compounds, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.90 GLP-1 Receptor Agonist Market: Distribution by Type of GLP-1 Agonist Drugs, 2020, Current Year and 2035

Table 34.91 GLP-1 Receptor Agonist Market for Long-acting GLP-1 Agonist, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.92 GLP-1 Receptor Agonist Market for Short-acting GLP-1 Agonist, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.93 GLP-1 Receptor Agonist Market: Distribution by GLP-1 Agonist, 2020, Current Year and 2035

Table 34.94 GLP-1 Receptor Agonist Market for Single-agonist, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.95 GLP-1 Receptor Agonist Market for Dual-agonist, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.96 GLP-1 Receptor Agonist Market for Tri-agonist, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.97 GLP-1 Receptor Agonist Market: Distribution by Route of Administration, 2020, Current Year and 2035

Table 34.98 GLP-1 Receptor Agonist Market for Oral Route, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.99 GLP-1 Receptor Agonist Market for Parental Route, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.100 GLP-1 Receptor Agonist Market: Distribution by Target Indication, 2020, Current Year and 2035

Table 34.101 GLP-1 Receptor Agonist Market for Alzheimer’s Disease, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.102 GLP-1 Receptor Agonist Market for Non-Alcoholic Steatohepatitis, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.103 GLP-1 Receptor Agonist Market for Obesity, Historical Trends Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.104 GLP-1 Receptor Agonist Market for Sleep Apnea, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.105 GLP-1 Receptor Agonist Market for Type 2 Diabetes, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.106 GLP-1 Receptor Agonist Market: Distribution by Geographical Regions, 2020, Current Year and 2035

Table 34.107 GLP-1 Receptor Agonist Market in North America, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.108 GLP-1 Receptor Agonist Market in the US, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.109 GLP-1 Receptor Agonist Market in Canada, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.110 GLP-1 Receptor Agonist Market in Europe, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.111 GLP-1 Receptor Agonist Market in Germany, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.112 GLP-1 Receptor Agonist Market in France, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.113 GLP-1 Receptor Agonist Market in the UK, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.114 GLP-1 Receptor Agonist Market in Italy, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.115 GLP-1 Receptor Agonist Market in Spain, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.116 GLP-1 Receptor Agonist Market in Rest of Europe, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.117 GLP-1 Receptor Agonist Market in Asia-Pacific, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.118 GLP-1 Receptor Agonist Market in China, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.119 GLP-1 Receptor Agonist Market in Japan, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.120 GLP-1 Receptor Agonist Market in South Korea, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.121 GLP-1 Receptor Agonist Market in Australia, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.122 GLP-1 Receptor Agonist Market in Rest of Asia-Pacific, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.123 GLP-1 Receptor Agonist Market in Latin America, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.124 GLP-1 Receptor Agonist Market in Brazil, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.125 GLP-1 Receptor Agonist Market in Argentina, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.126 GLP-1 Receptor Agonist Market in Rest of Latin America, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.127 Approved GLP-1 Drug, Feisumei (Benaglutide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.128 Approved GLP-1 Receptor Agonist Drug, Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scena

Table 34.129 Approved GLP-1 Receptor Agonist Drug, Mounjaro (Tirzepatide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.130 Approved GLP-1 Receptor Agonist Drug, Ozempic (Semaglutide Subcutaneous) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD

Table 34.131 Approved GLP-1 Receptor Agonist Drug, Rybelsus (Semaglutide Oral) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billio

Table 34.132 Approved GLP-1 Receptor Agonist Drug, Saxenda (Liraglutide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.133 Approved GLP-1 Receptor Agonist Drug, Trulicity (Dulaglutide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.134 Approved GLP-1 Receptor Agonist Drug, Victoza (Liraglutide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.135 Approved GLP-1 Receptor Agonist Drug, Wegovy (Semaglutide Subcutaneous) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD

Table 34.136 Approved GLP-1 Receptor Agonist Drug, XULTOPHY (Insulin Degludec / Liraglutide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenar

Table 34.137 Approved GLP-1 Receptor Agonist Drug, Zepbound (Tirzepatide) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.138 Phase III GLP-1 Receptor Agonist Drug, GMA102 / Glutazumab Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.139 Phase III GLP-1 Receptor Agonist Drug, JY09 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.140 Phase III GLP-1 Receptor Agonist Drug, LY3298176 / Tirzepatide Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.141 Phase III GLP-1 Receptor Agonist Drug, Mazdutide / LY3305677/ IBI-362 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Bi

Table 34.142 Phase III GLP-1 Receptor Agonist Drug, Orforglipron / LY3502970 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.143 Phase III GLP-1 Receptor Agonist Drug, PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast, Till 2035, Conservative, Base and Opt

Table 34.144 Phase III GLP-1 Receptor Agonist Drug, Retatrutide / LY3437943 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.145 Phase III GLP-1 Receptor Agonist Drug, Semaglutide Oral Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.146 Phase III GLP-1 Receptor Agonist Drug, Semaglutide Subcutaneous Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.147 Phase III GLP-1 Receptor Agonist Drug, Survodutide / BI 456906 Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.148 Phase III GLP-1 Receptor Agonist Drug, XW003 / Ecnoglutide Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.149 Phase III GLP-1 Receptor Agonist Drug, YN011-isupaglutide Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenario (USD Billion)

Table 34.150 GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in 2020 (USD Billion))

Table 34.151 GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales in the Current Year (USD Billion))

Table 34.152 GLP-1 Receptor Agonist Market: Distribution by Leading Drug Developers (in terms of GLP-1 drug sales estimated in 2035 (USD Billion))

GLP-1 Receptor Agonist Market Size, Share, Trends, Industry Analysis Report